REPORT ID 141063

Chimeric Antigen Receptor Car T Cell Therapy Market - Growth Opportunities, Future Trends, Covid-19 Impact, SWOT Analysis, Forecasts & Competition Tracking - Global Market Insights 2020 to 2028

Publish Date
Feb-21
Pages
250
Format
Electronic (PDF)

The report provides an overview of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market in several key countries spread across different geographic regions around the world. The report focuses on identifying various market trends, dynamics, growth drivers and factors restraining the market growth. Further, the report provides detailed insights into various growth opportunities and challenges based on various types of products, applications, end users and countries, among others. The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

The Key manufacturers that are operating in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market are:
Juno Therapeutics Inc. (A Celgene Company) Puretech Health Noile-Immune Biotech Celgene Corp. Editas Medicine Inc. Mustang Bio Inc. iCell Gene Therapeutics Novartis AG Shire Pharmaceuticals Inc. Avacta Life Sciences Ltd. Eureka Therapeutics Inc. Amgen Formula Pharmaceuticals Inc. Bluebird Bio Takeda Pharmaceuticals Celyad SA Gilead Sciences Protheragen Inc. Medimmune Llc/Astrazeneca Servier Laboratories Kite Pharma Inc. (A Subsidiary of Gilead Sciences Inc.) Cellectis Transgene SA F. Hoffman La Roche AG Bellicum Phamaceuticals

Report Scope:  
A holistic view of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market
Analysis of various regional market trends, along with quantitative data corresponding to market size for the years 2018 and 2019, estimates for 2020, and growth forecast for the period from 2021 to 2025
Attractive investment propositions in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market based on various segments such as product type, application, end user etc.
Key success factors and pain points in the form of growth drivers and restraints governing the market outlook along with future trend analysis
Detailed company profiles providing insights into their product offerings, strategies, revenue information and recent market activities
Information on industry value chain analysis of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market providing an investigative study of key stakeholders involved, which could expedite market participants in formulating appropriate strategies
Competitive landscape of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market and market share analysis based on company’s performance and customer reach

Report Overview:
This study was conducted with a global perspective in terms of the various segments in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. Market sizing and forecast have been conducted for 5 geographic regions: North America, Latin America, Europe, Middle East and Africa (MEA), and Asia-Pacific. All market sizing data is provided in US$ with historic data for the years 2018 and 2019, along with estimations and forecast for the period from 2020 to 2025.

The ongoing COVID-19 pandemic has had a significant impact on the overall international trade and businesses. This report provides the latest insights into the Chimeric Antigen Receptor (CAR) T-Cell Therapy market factoring in various effects of the industry disruptions and halts caused by COVID-19.

Market Segmentation:
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Type:
Acute Lymphoblastic Leukemia (ALL)
Advanced Lymphomas
Others

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Application:
Children
Adult

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market, by Geography:
North America
U.S.
Canada
Europe
UK
Germany
France
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East and Africa (MEA)
GCC Countries
South Africa
Rest of MEA
The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain in the air bearing spindle market. The report provide in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on air bearing spindle market segments and geographies.

Report Highlights:

Detailed overview of air bearing spindle market
Changing air bearing spindle market dynamics in the industry
In-depth market segmentation
Historical, current, and projected air bearing spindle market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on air bearing spindle market performance
Must-have information for air bearing spindle market players to sustain and enhance their market footprint
Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
			   
1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Overview
       1.1 Product Overview and Scope of Chimeric Antigen Receptor (CAR) T-Cell Therapy
       1.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Type
               1.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Growth Rate Comparison by Type (2020-2026)
               1.2.2 Product Acute Lymphoblastic Leukemia (ALL)
               1.2.3 Product Advanced Lymphomas
               1.2.4 Product Others
               1.2.5 Others
       1.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Application
               1.3.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Comparison by Application: (2020-2026)
               1.3.2 Children
               1.3.3 Adult
               1.3.4 Application 3
               1.3.5 Others
       1.4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Estimates and Forecasts
               1.4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue 2015-2026
               1.4.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales 2015-2026
               1.4.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region: 2020 Versus 2026
       1.5 Coronavirus Disease 2019 (Covid-19): Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Impact
               1.5.1 How the Covid-19 is Affecting the Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry
                            1.5.1.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Business Impact Assessment - Covid-19
                            1.5.1.2 Supply Chain Challenges
                            1.5.1.3 COVID-19's Impact On Crude Oil and Refined Products
               1.5.2 Market Trends and Chimeric Antigen Receptor (CAR) T-Cell Therapy Potential Opportunities in the COVID-19 Landscape
               1.5.3 Measures/Proposal against Covid-19
                            1.5.3.1 Government Measures to Combat Covid-19 Impact
                            1.5.3.2 Proposal for Chimeric Antigen Receptor (CAR) T-Cell Therapy Players to Combat Covid-19 Impact
       1.6 Study Objectives
       1.7 Years Considered

2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Competition by Manufacturers
       2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Market Share by Manufacturers (2015-2020)
       2.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Share by Manufacturers (2015-2020)
       2.3 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Average Price by Manufacturers (2015-2020)
       2.4 Manufacturers Chimeric Antigen Receptor (CAR) T-Cell Therapy Manufacturing Sites, Area Served, Product Type
       2.5 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Competitive Situation and Trends
               2.5.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Concentration Rate
               2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
               2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
       2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
       2.7 Primary Interviews with Key Chimeric Antigen Receptor (CAR) T-Cell Therapy Players (Opinion Leaders)

3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Retrospective Market Scenario by Region
       3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Retrospective Market Scenario in Sales by Region: 2015-2020
       3.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Retrospective Market Scenario in Revenue by Region: 2015-2020
       3.3 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Facts & Figures by Country
               3.3.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Country
               3.3.2 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Country
               3.3.3 U.S.
               3.3.4 Canada
       3.4 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Facts & Figures by Country
               3.4.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Country
               3.4.2 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Country
               3.4.3 Germany
               3.4.4 France
               3.4.5 U.K.
               3.4.6 Italy
               3.4.7 Russia
       3.5 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Facts & Figures by Region
               3.5.1 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Region
               3.5.2 Asia Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Region
               3.5.3 China
               3.5.4 Japan
               3.5.5 South Korea
               3.5.6 India
               3.5.7 Australia
               3.5.8 Taiwan
               3.5.9 Indonesia
               3.5.10 Thailand
               3.5.11 Malaysia
               3.5.12 Philippines
               3.5.13 Vietnam
       3.6 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Facts & Figures by Country
               3.6.1 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Country
               3.6.2 Latin America Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Country
               3.6.3 Mexico
               3.6.4 Brazil
               3.6.5 Argentina
       3.7 Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Facts & Figures by Country
               3.7.1 Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Country
               3.7.2 Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales by Country
               3.7.3 Turkey
               3.7.4 Saudi Arabia
               3.7.5 U.A.E
4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Historic Market Analysis by Type
       4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Market Share by Type (2015-2020)
       4.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Type (2015-2020)
       4.3 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Price Market Share by Type (2015-2020)
       4.4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Historic Market Analysis by Application
       5.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales Market Share by Application (2015-2020)
       5.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Application (2015-2020)
       5.3 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Price by Application (2015-2020)

6 Company Profiles and Key Figures in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business
        6.1 Juno Therapeutics Inc. (A Celgene Company)
                6.1.1 Corporation Information
                6.1.2 Juno Therapeutics Inc. (A Celgene Company) Description, Business Overview
                6.1.3 Juno Therapeutics Inc. (A Celgene Company) Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.1.4 Juno Therapeutics Inc. (A Celgene Company) Products Offered
                6.1.5 Juno Therapeutics Inc. (A Celgene Company) Recent Development
        6.2 Puretech Health
                6.2.1 Corporation Information
                6.2.2 Puretech Health Description, Business Overview
                6.2.3 Puretech Health Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.2.4 Puretech Health Products Offered
                6.2.5 Puretech Health Recent Development
        6.3 Noile-Immune Biotech
                6.3.1 Corporation Information
                6.3.2 Noile-Immune Biotech Description, Business Overview
                6.3.3 Noile-Immune Biotech Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.3.4 Noile-Immune Biotech Products Offered
                6.3.5 Noile-Immune Biotech Recent Development
        6.4 Celgene Corp.
                6.4.1 Corporation Information
                6.4.2 Celgene Corp. Description, Business Overview
                6.4.3 Celgene Corp. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.4.4 Celgene Corp. Products Offered
                6.4.5 Celgene Corp. Recent Development
        6.5 Editas Medicine Inc.
                6.5.1 Corporation Information
                6.5.2 Editas Medicine Inc. Description, Business Overview
                6.5.3 Editas Medicine Inc. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.5.4 Editas Medicine Inc. Products Offered
                6.5.5 Editas Medicine Inc. Recent Development
        6.6 Mustang Bio Inc.
                6.6.1 Corporation Information
                6.6.2 Mustang Bio Inc. Description, Business Overview
                6.6.3 Mustang Bio Inc. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.6.4 Mustang Bio Inc. Products Offered
                6.6.5 Mustang Bio Inc. Recent Development
        6.7 iCell Gene Therapeutics
                6.7.1 Corporation Information
                6.7.2 iCell Gene Therapeutics Description, Business Overview
                6.7.3 iCell Gene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.7.4 iCell Gene Therapeutics Products Offered
                6.7.5 iCell Gene Therapeutics Recent Development
        6.8 Novartis AG
                6.8.1 Corporation Information
                6.8.2 Novartis AG Description, Business Overview
                6.8.3 Novartis AG Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.8.4 Novartis AG Products Offered
                6.8.5 Novartis AG Recent Development
        6.9 Shire Pharmaceuticals Inc.
                6.9.1 Corporation Information
                6.9.2 Shire Pharmaceuticals Inc. Description, Business Overview
                6.9.3 Shire Pharmaceuticals Inc. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.9.4 Shire Pharmaceuticals Inc. Products Offered
                6.9.5 Shire Pharmaceuticals Inc. Recent Development
        6.10 Avacta Life Sciences Ltd.
                6.10.1 Corporation Information
                6.10.2 Avacta Life Sciences Ltd. Description, Business Overview
                6.10.3 Avacta Life Sciences Ltd. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.10.4 Avacta Life Sciences Ltd. Products Offered
                6.10.5 Avacta Life Sciences Ltd. Recent Development
        6.11 Eureka Therapeutics Inc.
                6.11.1 Corporation Information
                6.11.2 Eureka Therapeutics Inc. Description, Business Overview
                6.11.3 Eureka Therapeutics Inc. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.11.4 Eureka Therapeutics Inc. Products Offered
                6.11.5 Eureka Therapeutics Inc. Recent Development
        6.12 Amgen
                6.12.1 Corporation Information
                6.12.2 Amgen Description, Business Overview
                6.12.3 Amgen Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.12.4 Amgen Products Offered
                6.12.5 Amgen Recent Development
        6.13 Formula Pharmaceuticals Inc.
                6.13.1 Corporation Information
                6.13.2 Formula Pharmaceuticals Inc. Description, Business Overview
                6.13.3 Formula Pharmaceuticals Inc. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.13.4 Formula Pharmaceuticals Inc. Products Offered
                6.13.5 Formula Pharmaceuticals Inc. Recent Development
        6.14 Bluebird Bio
                6.14.1 Corporation Information
                6.14.2 Bluebird Bio Description, Business Overview
                6.14.3 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.14.4 Bluebird Bio Products Offered
                6.14.5 Bluebird Bio Recent Development
        6.15 Takeda Pharmaceuticals
                6.15.1 Corporation Information
                6.15.2 Takeda Pharmaceuticals Description, Business Overview
                6.15.3 Takeda Pharmaceuticals Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.15.4 Takeda Pharmaceuticals Products Offered
                6.15.5 Takeda Pharmaceuticals Recent Development
        6.16 Celyad SA
                6.16.1 Corporation Information
                6.16.2 Celyad SA Description, Business Overview
                6.16.3 Celyad SA Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.16.4 Celyad SA Products Offered
                6.16.5 Celyad SA Recent Development
        6.17 Gilead Sciences
                6.17.1 Corporation Information
                6.17.2 Gilead Sciences Description, Business Overview
                6.17.3 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.17.4 Gilead Sciences Products Offered
                6.17.5 Gilead Sciences Recent Development
        6.18 Protheragen Inc.
                6.18.1 Corporation Information
                6.18.2 Protheragen Inc. Description, Business Overview
                6.18.3 Protheragen Inc. Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.18.4 Protheragen Inc. Products Offered
                6.18.5 Protheragen Inc. Recent Development
        6.19 Medimmune Llc/Astrazeneca
                6.19.1 Corporation Information
                6.19.2 Medimmune Llc/Astrazeneca Description, Business Overview
                6.19.3 Medimmune Llc/Astrazeneca Chimeric Antigen Receptor (CAR) T-Cell Therapy Sales, Revenue and Gross Margin (2015-2020)
                6.19.4 Medimmune Llc/Astrazeneca Products Offered
                6.19.5 Medimmune Llc/Astrazeneca Recent Development
        6.20 Servier Laboratories
                6.20.1 Corporation Information
                6.20.2 Servier Laboratories Description, Business Overview